

CV SUMMARY

Doctorate in Biochemistry with European mention (2005); Doctorate Excellence Award. Dpto. Bioquímica y Biología Molecular (BBM), Universidad Complutense de Madrid (UCM). Supervisors: Dras. R. Rodríguez and M. Villalba. FPU-funded (*MECD, 2001*). Implementation of the component-resolved diagnosis (CRD) concept in allergy. 3-month stay in 2002 with Dr. R. Valenta (*AKH Hospital, Austria*). Solid background in techniques and methodologies related to protein chemistry and Molecular Biology.

Assistant Professor at BBM, UCM (2006-08). I combined my teaching responsibilities with my research duties. Our main finding was to discover the first allergen from olive fruit involved in occupational allergy (*Palomares et al. New Engl J Med 2008*).

Postdoctoral researcher (2008-10). *Swiss Institute of Allergy and Asthma Research (SIAF)*, Davos, Switzerland. Mentor: Dr. C. Akdis. Fulbright-MEC/FECYT Scholarship Program. We showed that tonsils are organs where tolerance induction to allergens occur by generation of FOXP3⁺ Tregs. The quality of these studies was recognized with the 2 most prestigious awards from EAACI and AAAAI to young researchers for scientific trajectories. Solid background in the state-of-the-art techniques and methodologies related to Immunology and great capacity to lead scientific research projects.

Research Associate - Ramon y Cajal Scholar and Group Leader of the Vaccines and Dendritic Cells Lab. at BBM, Chemistry School, UCM (Jan 2012- May 2018). In April 2010, I turned back to my position as Assistant Professor. In January 2012, I obtained a RyC contract at BBM, UCM. Since then, I have obtained public and private funding, which has allowed me to create and consolidate an independent research group (www.oscarpalomaresgroup.com), twitter: @Palomares_Lab.

Associate Professor at BBM, UCM (June 2018- continue). My lines of research are focused on the study of human DCs and ECs in the context of allergy and other inflammatory conditions to identify novel therapeutic targets for the development of innovative vaccines for allergy and other immune mediated disorders. In June 2021, I was awarded with EAACI PhARF award 2021 during the annual congress in Krakow (Poland) in recognition to my scientific trajectory.

1. LIST OF PUBLICATIONS

132 publications in world leading peer-reviewed international journals (100 in Q1) and 6 book chapters. Total times cited: 5091; Average of times cited per year (last 5 years): 692; Average citations per item: 27.82; h-index: 36 (Web of Science). Dr. Palomares has **co-authored 20 EAACI Task Forces** in Allergy (IF: 14.710). He has **co-chaired the elaboration of clinical guidelines on the use of Biologicals in allergic diseases**, leading to share last authorship in 7 systematic reviews and 3 clinical guidelines in Allergy (IF: 14.710).

- **Original Articles (68):**

1. Martín-Cruz L, Angelina A, Baydemir I, Bulut Ö, Subiza JL, Netea MG, Domínguez-Andrés J, **Palomares O***. *Candida albicans* V132 induces trained immunity and enhances the responses triggered by the polybacterial vaccine MV140 for genitourinary tract infections. **Front Immunol.** 2022;24;13:1066383. doi: 10.3389/fimmu.2022.1066383. **IF: 8.786** *Corresponding author
2. Benito-Villalvilla C, de la Rocha-Muñoz A, López-Abente J, Egel A, Bottoli I, Severin T, Woisetschläger M, **Palomares O***. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN- α production and FOXP3⁺ Treg generation. **Allergy.** 2022. doi: 10.1111/all.15567. **IF: 14.710** *Corresponding author
3. Maza-Solano J, Calvo-Henríquez C, Alobid I, Álvarez-Cendrero M, **Palomares O**, Moreno-Luna R, Santos-Perez J, González-García J, Sánchez-Gómez S. Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study. **J Clin Med.** 2022;29;11(23):7056. **IF: 4.964**
4. Hanif T, Ivaska LE, Ahmad F, Tan G, Mikola E, Puhakka T, **Palomares O**, Akdis CA, Toppila-Salmi S, Jartti T. Tonsillar transcriptional profiles in atopic and non-atopic subjects. **Allergy.** 2022. doi: 10.1111/all.15458. **IF: 14.710**
5. Angelina A, Jiménez-Saiz R, Pérez-Diego M, Maldonado A, Rückert B, Akdis M, Martín-Fontecha M, Akdis CA, **Palomares O***. Cannabinoid WIN55212-2 impairs peanut-allergic sensitization and promotes the generation of allergen-specific regulatory T cells. **Clin Exp Allergy.** 2022; 52(4):540-9. **IF: 5.401** *Corresponding author
6. Angelina A, Pérez-Diego M, Maldonado A, Rückert B, Akdis M, Martín-Fontecha M, Akdis CA, **Palomares O***. The cannabinoid WIN55212-2 suppresses effector T cell responses and promotes regulatory T cells in human tonsils. **Allergy.** 2022; 77(3):1029-1032. **IF: 14.710** *Corresponding author
7. Benito-Villalvilla C, Pérez-Diego M, Subiza JL, **Palomares O***. Allergoid-mannan conjugates imprint tolerogenic features in human macrophages. **Allergy.** 2022;77(1):320-323. **IF: 14.710** *Corresponding author
8. Angelina A, Pérez-Diego M, López-Abente J, Rückert B, Nombela I, Akdis M, Martín-Fontecha M, Akdis C, **Palomares O***. Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprogramming. **Mucosal Immunol.** 2022;15(1):96-108. **IF: 8.701** *Corresponding author

9. Ivaska LE, Silvoniemi A, **Palomares O**, Turunen R, Waris M, Mikola E, Puhakka T, Söderlund-Venermo M, Akdis M, Akdis CA, Jartti T. Persistent human bocavirus 1 infection and tonsillar immune responses. **Clin Transl Allergy**. **2021**; 11(6):e12030. doi: 10.1002/ct2.12030. **IF: 5.871**
10. Benito-Villalvilla, C., Pérez-Diego, M., Angelina, A., Kisand, K., Rebane, A., Subiza, J. L., & **Palomares, O***. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. **J Allergy Clin Immunol**. **2022**; 149(1):212-222.e9. **IF: 10.793** ***Corresponding author**
11. López-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, **Palomares O***. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3⁺Tregs. **Eur Respir J**. **2021**;57(1):2000751. doi: 10.1183/13993003.00751-2020. **IF: 33.795** ***Corresponding author**
12. Martin-Cruz L, Sevilla-Ortega C, Benito-Villalvilla C, Diez-Rivero CM, Sanchez-Ramón S, Subiza JL, Palomares O.* A Combination of Polybacterial MV140 and Candida albicans V132 as a Potential Novel Trained Immunity-Based Vaccine for Genitourinary Tract Infections. **Front Immunol**. **2021**;11:612269. doi:10.3389/fimmu.2020.612269. **IF: 8.786** ***Corresponding author**
13. Angelina A, Martín-Fontecha M, Rückert B, Wawrzyniak P, Pérez-Diego M, López-Abente J, Akdis M, Akdis CA, **Palomares O.*** The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption. **Allergy**. **2021**: 76(6):1900-1902. doi: 10.1111/all.14707. **IF: 14.710** ***Corresponding author**
14. Benito-Villalvilla C, Soria I, Pérez-Diego M, Fernández-Caldas E, Subiza JL, **Palomares O.*** Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs. **Allergy**. **2020**;75(3):648-659. doi: 10.1111/all.14036. **IF: 13.146** ***Corresponding author**
15. Mikola E, **Palomares O**, Turunen R, Waris M, Ivaska LE, Silvoniemi A, Puhakka T, Rückert B, Vuorinen T, Akdis M, Akdis CA, Jartti T. Rhinovirus species and tonsillar immune responses. **Clin Transl Allergy**. **2019**;9:63. doi: 10.1186/s13601-019-0302-7. **IF: 4.923**
16. Coronado S, Zakzuk J, Regino R, Ahumada V, Benedetti I, Angelina A, Palomares O, Caraballo L. *Ascaris lumbricoides* Cystatin Prevents Development of Allergic Airway Inflammation in a Mouse Model. **Front Immunol**. **2019**;10:2280. doi: 10.3389/fimmu.2019.02280. **IF: 4.716**
17. Mikola, E., Elenius, V., Saarinen, M., **Palomares, O.**, Waris, M., Turunen, R., Puhakka, P., Ivaska, L., Rückert, B., Aab, A., Vahlberg, T., Vuorinen, V., Allander, T., Camargo, C., Akdis, M., Akdis, C., Jartti, T. Tonsillar cytokine expression between patients with tonsillar hypertrophy and recurrent tonsillitis. **Clin Trans Allergy**. **2018**;8:22-30. **IF: 3.239**
18. Palladino C, Narzt MS, Bublin M, Schreiner M, Humeniuk P, Gschwandtner M, Hafner C, Hemmer W, Hoffmann-Sommergruber K, Mildner M, **Palomares O**, Gruber F, Breiteneder H. Peanut lipids display potential adjuvanticity by triggering a pro-inflammatory response in human keratinocytes. **Allergy**. **2018**;73:1746-1749. **IF: 6.048**

19. Hernández-Torres G, Enríquez-Palacios E, Mecha M, Feliú A, Rueda-Zubiaurre A, Angelina A, Martín-Cruz L, Martín-Fontecha M, **Palomares O**, Guaza C, Peña-Cabrera E, López-Rodríguez ML, Ortega-Gutiérrez S. Development of a fluorescent bodipy probe for visualization of the serotonin 5-HT_{1A} receptor in native cells of the immune system. **Bioconjug Chem.** **2018**;29:2021-2027. **IF: 4.818**
20. Soria, I., López-Relaño, J., Viñuela, M., Tudela, J.I., Angelina, A., Benito-Villalvilla, C., Díez-Rivero, C.M., Cases, B., Manzano, A.I., Fernández-Caldas, E., Casanovas, M., **Palomares, O.**, Subiza, J.L. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. **Allergy.** **2018**;73:875-884. **IF: 6.048**
21. Martín-Fontecha, M., Angelina, A., Rückert, B., Rueda-Zubiaurre, A., Martín-Cruz, L., van de Veen, W., Akdis, M., Ortega-Gutiérrez, S., López-Rodríguez, M.L., Akdis, C.A., **Palomares, O***. A fluorescent probe to unravel functional features of cannabinoid receptor CB1 in human blood and tonsil immune system cells. **Bioconjug Chem.** **2018**;21:382-389. **IF: 4.818** ***Corresponding author**
22. Komlósi, Z.I., Kovács, N., van de Veen, W., Kirsch, A.I., Fahrner, H.B., Wawrzyniak, M., Rebane, A., Stanic, B., **Palomares, O.**, Rückert, B., Menz, G., Akdis, M., Losonczy, G., Akdis, C.A. Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells. **J Allergy Clin Immunol.** **2108**;142:178-194. **IF: 13.081**
23. Cirauqui, C., Benito-Villalvilla, C., Sánchez-Ramón, S., Sirvent, S., Díez-Rivero, C.M., Conejero, L., Brandi, P., Hernández-Cillero, L., Ochoa, J.L., Pérez-Villamil, B., Sancho, D., Subiza, J.L., **Palomares, O***. Human dendritic cells activated with MV130 induce Th1, Th17 and IL-10 responses via RIPK2 and MyD88 signalling pathways. **Eur J Immunol.** **2018**;48:180-193. **IF: 4.227** ***Corresponding author**
24. Soria, I., Alvarez, J., Manzano, A.I., López-Relaño, J., Cases, B., Mas-Fontao, A., Cañada, F.J., Fernández-Caldas, E., Casanovas, M., Jiménez-Barbero, J., **Palomares, O.**, Viñals-Flórez, L.M., Subiza, J.L. Mite allergoids coupled to nonoxidized mannan from *Saccharomyces cerevisiae* efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. **Vet Immunol Immunopathol.** **2017**;190:65-72. **IF: 1.718**
25. Rodríguez-Pérez, N., Schiavi, E., Frei, R., Ferstl, R., Wawrzyniak, P., Smolinska, S., Sokolowska, M., Sievi, N.A., Kohler, M., Schmid-Grendelmeier, P., Michalovich, D., Simpson, K.D., Hessel, E.M., Jutel, M., Martín-Fontecha, M., **Palomares, O.**, Akdis, C.A., O'Mahony, L. Altered fatty acid metabolism and reduced stearoyl-coenzyme a desaturase activity in asthma. **Allergy.** **2017**;72:1744-1752. **IF: 7.361**
26. Elenius, V., **Palomares, O.**, Waris, M., Turunen, R., Puhakka, T., Rückert, B., Vuorinen, T., Allander, T., Vahlberg, T., Akdis, M., Camargo, C.A.Jr., Akdis, C.A., Jartti, T. The relationship of serum vitamins A, D, E and LL-37 levels with allergic status, tonsillar virus detection and immune response. **PLoS One.** **2017**;12:1405. doi: 10.1371/journal.pone.0172350. **IF: 3.541**

27. **Palomares, O***, Subiza, J.L. Reply to “Human basophils may not undergo modulation by DC-SIGN and mannose receptor–targeting immunotherapies due to absence of receptors”. **J Allergy Clin Immunol.** 2017;139:1405. IF: 13.081 ***Corresponding author**
28. Benito-Villalvilla, C., Cirauqui, C., Diez-Rivero, C.M., Casanovas, M., Subiza, J.L., **Palomares, O*** MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. **Mucosal Immunol.** 2017;10:924-935. IF: 7.478 ***Corresponding author**
29. Sirvent, S., Soria, I., Cirauqui, C., Cases, B., Manzano, A.I., Diez-Rivero, C.M., Reche, P.A., López-Relaño, J., Martínez-Naves, E., Cañada, F.J., Jiménez-Barbero, J., Subiza, J., Casanovas, M., Fernández-Caldas, E., Subiza, J.L., **Palomares, O***. Novel vaccines targeting dendritic cells by coupling allergoids to non-oxidized mannan enhance allergen uptake and induce functional regulatory T cells via PD-L1. **J Allergy Clin Immunol.** 2016;138:558-567: IF: 13.081 ***Corresponding author**
30. Angelina, A., Sirvent, S., Palladino, C., Vereda, A., Cuesta-Herranz, J., Eiwegger, T., Rodríguez, R., Breiteneder, H., Villalba, M., **Palomares, O***. The lipid-interaction capacity of Sin a 2 and Ara h 1, major mustard and peanut allergens of the cupin superfamily, endorses allergenicity. **Allergy.** 2016;71:1284-1294. IF: 6.028 ***Corresponding author**
31. Manzano, A.I., Cañada F.J., Cases, B., Sirvent, S., Soria, I., **Palomares, O.**, Fernández-Caldas, E., Casanovas, M., Jiménez-Barbero, J., Subiza, J.L. Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. **Glycoconj J.** 2016;33:93-101. IF: 2.520
32. Gamó, A.M., González-Vera, J.A., Rueda-Zubiaurre, A., Alonso, D., Vázquez-Villa, H., Martín-Couce, L., **Palomares, O.**, López, J.A., Martín-Fontecha, M., Benhamú, B., López-Rodríguez, M.L., Ortega-Gutiérrez, S. Chemoproteomic approach to explore the target profile of GPCR ligands: Application to 5-HT1A and 5-HT6 receptors. **Chemistry Eur J.** 2016;22:1313-1321. IF: 5.731
33. Torres, M., **Palomares, O.**, Quiralte, J., Pauli, G., Rodríguez, R., Villalba, M. An enzymatically active β -1,3-glucanase from ash pollen with allergenic properties: a particular member in the Oleaceae family. **PlosOne.** 2015;10:e0133066. doi: 10.1371/journal.pone.0133066. IF: 3.534
34. Sirvent, S., Cantó, B., Gómez, F., Blanca, N., Cuesta-Herranz, J., Canto, G., Blanca, M., Rodríguez, R., Villalba, M., **Palomares, O*** Detailed characterization of Act d 12 and Act d 13 from kiwi seeds: implication in IgE cross-reactivity with peanut and tree nuts. **Allergy.** 2014;69:1481-1488. IF: 6.028 ***Corresponding author**
35. Torres, M., Alvarez-García, E., Bartra, J., Alcántara, M., **Palomares, O.**, Villalba, M., Rodríguez, R. The allergenic structure of the thaumatin-like protein Ole e 13 is shattered by processing of raw olive fruits. **J Invest Allergy Clin Immunol.** 2014;24:162-168. IF: 2.642
36. Sirvent, S., Cantó, B., Cuesta-Herranz, J., Gómez, F., Blanca, N., Canto, G., Blanca, M., Rodríguez, R., Villalba, M., **Palomares, O*** Act d 12 and Act d 13: Two novel, masked, relevant

- allergens in kiwifruit sedes. **J Allergy Clin Immunol.** 2014;133:1765-1764: **IF: 11.476**
***Corresponding author**
37. Zaleska, A., Eiwegger, T., Soyer, O., van de Veen, W., Rhyner, C., Soyka, M.B., Bekpen, C., Demiröz, D., Treis, A., Söllner, S., **Palomares, O.**, Kwok, W.W., Rose, H., Senti, G., Kündig, T.M., Ozoren, N., Jutel, M., Akdis, C.A., Cramer, R., Akdis, M. Immune regulation by intralymphatic immunotherapy with modular allergen-translocation MAT vaccine. **Allergy** 2014;69:1162-1170. **IF: 6.028**
38. Jartti, T., **Palomares, O.**, Waris, M., Tastan, O., Nieminen, R., Puhakka, T., Rückert, B., Aab, A., Vuorinen, T., Allander, T., Vahlberg, T., Ruuskanen, O., Akdis, M., Akdis, C.A. Distinct regulation of tonsillar immune response in virus infection. **Allergy.** 2014;69:658-667. **IF: 6.028**
39. Martín-Fontecha, M., Eiwegger, T., Jartti, T., Rueda-Zubiaurre, A., Tiringier, K., Stepanow, J., Puhakka, T., Rückert, B., Ortega-Gutiérrez, S., López-Rodríguez, M.L., Akdis, M., Akdis, C.A., **Palomares, O.*** The expression of cannabinoid receptor 1 is significantly increased in atopic patients. **J Allergy Clin Immunol.** 2014;133:926-929. **IF: 11.476** ***Corresponding author**
40. Küçüksezer, U.*, **Palomares, O.***, Rückert, B., Jartti, T., Puhakka, T. Nandy A., Fahrner H.B., Jung, A., Gemicioğlu, B., Deniz, G., Akdis, C., Akdis, M. Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T cell tolerance in human tonsils and peripheral blood. **J Allergy Clin Immunol.** 2013;131:875-885. **IF: 12.047** ***Contributed equally, share first authorship**
41. Sirvent, S., Akotenou, M., Cuesta-Herranz, J., Vereda, A., Rodríguez, R., Villalba, M., **Palomares, O.*** The 11S globulin Sin a 2 from yellow mustard seeds shows IgE cross-reactivity with homologous counterparts from tree nuts and peanut. **Clin Transl Allergy.** 2012;11:1-23. **IF: 2.530**
***Corresponding author**
42. Martín-Couce, L., Martín-Fontecha, M., **Palomares, O.**, Mestre, L., Cordoní, M.H., Palma, S., Pardo, L., Guaza, C., López-Rodríguez, M.L., Ortega-Gutiérrez, S. Chemical probes for the recognition of cannabinoid receptors in native systems. **Angew Chem Int Ed.** 2012;51:6896-6899. **IF: 13.455**
43. Sirvent, S., **Palomares, O.**, Cuesta-Herranz, J., Villalba, M., Rodríguez, R. Analysis of the structural and immunological stability of 2S albumins, non-specific lipid transfer protein, and profilin allergens from mustard seeds. **J Agri Food Chem.** 2012;60:6011-6018: **IF: 2.906**
44. **Palomares, O.***, Rückert, B., Jartti, T., Küçüksezer, U., Puhakka, T. Gomez, E., Fahrner, H.B., Speiser, A., Jung, A., Kwok, W.W., Kalogjera, L., Akdis, M. and Akdis, C.A.* Induction and maintenance of allergen-specific FOXP3+ Treg cells in human tonsils as first line organs of oral tolerance. **J Allergy Clin Immunol.** 2012;129:510-520. **IF: 11.003** ***Corresponding author**
45. **Palomares, O.**, O'Mahony, L., Akdis, C.A. The many routes of dendritic cells to ensure immune regulation. **J Allergy Clin Immunol.** 2011;127:1541-1542. **IF: 11.003**

46. Vereda, A., Sirvent, S., Villalba, M., Rodríguez, R., Cuesta-Herranz, J., **Palomares, O.*** Improvement of mustard allergy (*Sinapis alba*) diagnosis and management by linking clinical features and component-resolved approaches. **J Allergy Clin Immunol.** **2011**;127:1304-1307. **IF: 11.003** ***Corresponding author**
47. Sirvent, S., **Palomares, O.**, Vereda, A., Villalba, M., Cuesta-Herranz, J., Rodríguez, R. nsLTP and profilin are allergens in mustard seeds: cloning, sequencing and recombinant production of Sin a 3 and Sin a 4. **Clin Exp Allergy.** **2009**;206:1929-1936. **IF: 4.084**
48. Klunker, S., Chong, M.M.W., Mantel, P.Y., **Palomares, O.**, Bassin, C., Ziegler, M., Rückert, B., Meiler, F., Akdis, M., Littman, D. R., Akdis, A. C. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. **J Exp Med.** **2009**;206:2701-2715. **IF: 14.505**
49. Popolo, L., Ragni, E., Carotti, C., **Palomares, O.**, Aardema, R., Back, J.W., Dekker, H.L., de Koning, L.J., de Jong, L., de Koster, C.G. Disulfide bond structure and domain organization of yeast beta (1,3)-glucanotransferases involved in cell wall biogenesis. **J Biol Chem.** **2008**;283:18553-18565. **IF: 5.520**
50. **Palomares, O.**, Fernández-Nieto, M., Villalba, M., Rodríguez, R., Cuesta-Herranz, J. Occupational allergy in a researcher worker due to Ole e 9, an allergenic 1,3-beta-glucanase from olive pollen. **Allergy.** **2008**;63:784-785. **IF: 6.204**
51. Treviño, M.A., **Palomares, O.**, Castrillo, I., Villalba, M., Rodríguez, R., Rico, M., Santoro, J., Bruix, M. Solution structure of the C-terminal domain of Ole e 9, a major allergen of olive pollen. **Protein Sci.** **2008**;17:371-376. **IF: 3.115**
52. **Palomares, O.**, Alcántara, M., Quiralte, J., Villalba, M., Garzón, F., Rodríguez, R. A thaumatin-like protein and occupational airway disease in an olive-oil mill worker. **N Engl J Med.** **2008**;358:1306-1308. **IF: 50.017**
53. Compés, E., **Palomares, O.**, Fernández-Nieto, M., Escudero, C., Cuesta-Herranz, J. Allergy to turnip seeds in a bird fancier. **Allergy.** **2007**;62:1472-1473. **IF: 5.014**
54. **Palomares, O.**, Vereda, A., Cuesta-Herranz, J., Villalba, M., Rodríguez, R. Cloning, sequencing, and recombinant production of Sin a 2, an allergenic 11S globulin from yellow mustard seeds. **J Allergy Clin Immunol.** **2007**;119:1189-1196. **IF: 8.115**
55. Castrillo, I., Treviño, M.A., **Palomares, O.**, Rico, M., Santoro, J., Bruix, M. NMR assignment of the C-terminal domain of Ole e 9, a major allergen from olive pollen tree. **J Biomol NMR.** **2006**;67:1-7. **IF: 1.791**
56. **Palomares, O.**, Villalba, M., Quiralte, J., Rodríguez R. Allergenic contribution of the IgE-reactive domains of the 1,3-β-glucanase Ole e 9: diagnostic value in olive pollen allergy. **Ann Allergy Asth Immunol.** **2006**;97:61-65. **IF: 2.254**

57. **Palomares, O.**, Swoboda, I., Villalba, M., Spitzauer, S., Rodríguez, R., Valenta, R. The major allergen of olive pollen Ole e 1 is a diagnostic marker for sensitization to *oleaceae*. **Int Arch Allergy Immunol.** 2006;141:110-118. **IF: 2.524**
58. Duffort, O., **Palomares, O.**, Lombardero, M., Villalba, M., Barber, D., Rodríguez, R., Polo, F. Variability of Ole e 9 in olive pollen extracts. Relevance of minor allergens in immunotherapy treatments. **Int Arch Allergy Immunol.** 2006;140:131-138. **IF: 2.524**
59. Compés, E., Hernández, E., Quirce, S., **Palomares, O.**, Rodríguez, R., Cuesta, J., Sastre, J., Villalba, M. Hypersensitivity to black locust (*Robinia pseudoacacia*) pollen: "allergy mirages". **Ann Allergy Asth Immunol.** 2006;96:586-592. **IF: 2.254**
60. **Palomares, O.**, Batanero, E., Cañamero, M., Villalba, M., Rodríguez, R. Prophylactic intranasal treatment with fragments of 1,3- β -glucanase olive pollen allergen prevents airway inflammation in a murine model of type I allergy. **Int. Arch. Allergy Immunol.** 2006;139:175-180. **IF: 2.524**
61. **Palomares, O.**, Cuesta-Herranz, J., Vereda, A., Sirvent, S., Villalba, M., and Rodríguez, R. Isolation and identification of an 11S globulin as a new major allergen in mustard seeds. **Ann Allergy Asthma Immunol.** 2005;94:586-592. **IF: 1.987**
62. **Palomares, O.**, Cuesta-Herranz, J., Rodríguez, R., Villalba, M. A recombinant precursor of the mustard allergen Sin a 1 retains the biochemical and immunologic features of the heterodimeric native protein. **In. Arch Allergy Immunol.** 2005;137:18-26. **IF: 2.201**
63. **Palomares, O.**, Villalba, M., Quiralte, J., Polo, F., Rodríguez, R. 1,3- β -glucanases as solid candidates to be involved in latex-pollen-vegetable food cross-reactivity. **Clin Exp. Allergy.** 2005;35:345-351. **IF: 3.553**
64. Pantoja-Uceda, D., **Palomares, O.**, Bruix, M., Villalba, M., Rodríguez, R., Rico, M., Santoro, J. Solution structure and stability against digestion of rproBnlb, a recombinant 2S albumin from rapeseed: relationship to its allergenic properties. **Biochemistry.** 2004;43:16036-16045. **IF: 4.008**
65. Carotti, C., Ragni, E., **Palomares, O.**, Fontaine, T., Tedeschi, G., Rodríguez, R., Latgé, J.P., Vai, M., Popolo, L. Characterization of recombinant forms of the yeast Gas1 protein and identification of residues essential for glucanosyltransferase activity and folding. **Eur J Biochem.** 2004;271:3635-3645. **IF: 3.260**
66. Barral, P., Batanero, E., **Palomares, O.**, Quiralte, J., Villalba, M., and Rodríguez, R. A major allergen from pollen defines a novel family of plant proteins and shows intra- and interspecies cross-reactivity. **J Immunol.** 2004;172:3644-3651. **IF: 6.486**
67. **Palomares, O.**, Villalba, M., Rodríguez, R. The C-terminal segment of the 1,3- β -glucanase Ole e 9 from olive (*Olea europaea*) pollen is an independent domain with allergenic activity: expression in *Pichia pastoris* and characterization. **Biochem J.** 2003;369:593-601. **IF: 4.101**

68. Palomares, O., Monsalve, R.I., Rodríguez, R., Villalba, M. Recombinant pronapin precursor produced in *Pichia pastoris* displays structural and immunologic equivalent properties to its mature product isolated from rapeseed. **Eur J Biochem.** **2002**;269:2538-2545. **IF: 2.999**

• **Reviews (27):**

1. Angelina A, Martín-Cruz L, de la Rocha-Muñoz A, Lavín-Plaza B, **Palomares O***. C-Type Lectin Receptor Mediated Modulation of T2 Immune Responses to Allergens. **Curr Allergy Asthma Rep.** **2023** Feb 1. doi: 10.1007/s11882-023-01067-0. **IF: 4.919** ***Corresponding author**
2. Martín-Cruz L, Sevilla-Ortega C, Angelina A, Domínguez-Andrés J, Netea MG, Subiza JL, Palomares O. From trained immunity in allergy to trained immunity-based allergen vaccines. **Clin Exp Allergy.** **2022**. doi: 10.1111/cea.14261. **IF: 5.401** ***Corresponding author**
3. Satitsuksanoa P, Angelina A, **Palomares O***, Akdis M. Mechanisms in AIT: Insights 2021. **Allergol Select.** **2022**; 21;6:259-266. **IF: 4.200** ***Corresponding author**
4. **Palomares O***, Elewaut D, Irving PM, Jaumont X, Tassinari P. Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity? **Allergy.** **2022** doi: 10.1111/all.15449. **IF: 14.710** ***Corresponding author**
5. Subiza JL, **Palomares O**, Quinti I, Sánchez-Ramón S. Editorial: Trained Immunity-Based Vaccines. **Front Immunol.** **2021**; 24;12:716296. doi: 10.3389/fimmu.2021.716296. **IF: 8.701**
6. Pfaar O, Creticos PS, Kleine-Tebbe J, Canonica GW, **Palomares O**, Schülke S. One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. **J Allergy Clin Immunol Pract.** **2021**; 9(5):1791-1803. **IF: 11.022**
7. Bachert C, Maurer M, **Palomares O**, Busse WW. What is the contribution of IgE to nasal polyposis? **J Allergy Clin Immunol.** **2021**; 147(6):1997-2008. **IF: 13.769**
8. Bousquet J, Anto JM, Bachert C, Baiardini I, Bosnic-Anticevich S, Walter Canonica G, Melén E, **Palomares O**, Scadding GK, Togias A, Toppila-Salmi S. Allergic rhinitis. **Nat Rev Dis Primers.** **2020**;6(1):95. doi: 10.1038/s41572-020-00227-0. **IF: 40.689**
9. Akdis CA, Arkwright PD, Brügggen MC, Busse W, Gadina M, Guttman-Yassky E, Kabashima K, Mitamura Y, Vian L, Wu J, **Palomares O**. Type 2 immunity in the skin and lungs. **Allergy.** **2020**;75(7):1582-1605. doi: 10.1111/all.14318. **IF: 13.146**
10. Angelina A, Pérez-Diego M, López-Abente J, Palomares O. The Role of Cannabinoids in Allergic Diseases: Collegium Internationale Allergologicum (CIA) Update 2020. **Int Arch Allergy Immunol.** **2020**;181(8):565-584. doi: 10.1159/000508989. **IF: 2.917**
11. Palomares O, Untersmayr E, Gutermuth J, Agache I, Ajeganova S, Bavbek S, Chan S, Jutel M, Quirce S, Schmid-Grendelmeier P, Schmidt-Weber C, Torres MJ, Eiwegger T. Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of

- the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019. **Allergy**. **2020**;75(4):936-940. doi: 10.1111/all.14024. **IF:13.146**
12. Seys SF, Quirce S, Agache I, Akdis CA, Alvaro-Lozano M, Antolín-Amérigo D, Bjermer L, Bobolea I, Bonini M, Bossios A, Brinkman P, Bush A, Calderon M, Canonica W, Chanez P, Couto M, Davila I, Del Giacco S, Del Pozo V, Erjefält JS, Gevaert P, Hagedoorn P, G Heaney L, Heffler E, Hellings PW, Jutel M, Kalayci O, Kurowski MM, Loukides S, Nair P, Palomares O, Polverino E, Sanchez-Garcia S, Sastre J, Schwarze J, Spanevello A, Ulrik CS, Usmani O, Van den Berge M, Vasakova M, Vijverberg S, Diamant Z. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018. **Allergy**. **2019**;74(11):2244-2248. doi: 10.1111/all.13843. **IF: 6.280**
 13. Humbert M, Bousquet J, Bachert C, Palomares O, Pfister P, Kottakis I, Jaumont X, Thomsen SF, Papadopoulos NG. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. **J Allergy Clin Immunol Pract**. **2019**;7(5):1418-1429. doi: 10.1016/j.jaip.2019.02.030. **IF: 8.132**
 14. Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. **Front Immunol**. **2018**;9:2936. doi: 10.3389/fimmu.2018.02936. **IF: 4.683**
 15. Benito-Villalvilla C., Soria I., Subiza J.L., **Palomares O***. Novel vaccines targeting dendritic cells by coupling allergoids to mannan. **Allergo J Int**. **2018**;27:256-262. ***Corresponding author**
 16. Klimek L, Kündig T, Kramer MF, Guethoff S, Jensen-Jarolim E, Schmidt-Weber CB, Palomares O, Mohsen MO, Jakob T, Bachmann M. Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. **Allergo J Int**. **2018**;27(8):245-255. doi: 10.1007/s40629-018-0074-y.
 17. Domingo C, Palomares O, Sandham DA, Erpenbeck VJ, Altman P. The prostaglandin D₂ receptor 2 pathway in asthma: a key player in airway inflammation. **Respir Res**. **2018**;19(1):189. doi: 10.1186/s12931-018-0893-x. **IF: 3.975**
 18. Larenas-Linnemann, D., Nieto, A., **Palomares, O.**, Pitrez, P.M., Cukier, G. Moving toward consensus on diagnosis and management of severe asthma in children. **Current Med Res Opin**. **2018**;34:447-458. **IF: 2.757**
 19. Colodenco, D., **Palomares, O.**, Celis, C., Kaplan, A., Domingo, C. Moving toward consensus on diagnosis and management of severe asthma in adults. **Current Med Res Opin**. **2018**;34:387-399. **IF: 2.757**
 20. **Palomares, O.**, Akdis, M., Martín-Fontecha, M., Akdis, C.A. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. **Immunol Rev**. **2017**;278:219-236. **IF: 9.614**
 21. **Palomares, O.**, Sánchez-Ramón, S., Dávila, I., Prieto, L., Pérez de Llano, L., Lleonart, M., Domingo, C., Nieto, A. dlvergEnt: How IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies. **Int J Mol Sci**. **2017**;18:E1328. doi: 10.3390/ijms18061328. **IF: 3.226**

22. Tejera-Alhambra, M., **Palomares, O.**, Perez de Diego, R., Diaz-Lezcano, I., Sanchez-Ramon, S. New biological insights in the immunomodulatory effects of mucosal polybacterial vaccines in clinical practice. **Curr Pharm Des.** 2016;22:6283-6293. **IF: 2.611**
 23. **Palomares, O.***, Cramer, R., Rhyner, C. The contribution of biotechnology towards progress in diagnosis, management, and treatment of allergic diseases. **Allergy.** 2014;69:1588-1601. **IF: 6.028**
 24. **Palomares, O.**, Martín-Fontecha, M., Lauener, R., Traidl-Hoffmann, C., Bircan, O., Akdis, M., Akdis C.A. Regulatory T cells and immune regulation of allergic diseases: roles of IL-10 and TGF-beta. **Genes and Immunity.** 2014;15:511-520. **IF: 3.675**
 25. **Palomares, O.** The role of regulatory T cells in IgE-mediated food allergy. **J Invest Allergy Clin Immunol.** 2013;23:371-382. **IF: 2.642**
 26. Akdis, M., **Palomares, O.**, Van de Veen, W., van Splunter, M., Akdis, C.A. Th17 and Th22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. **J Allergy Clin Immunol.** 2012;129:1438-1449. **IF: 12.047**
 27. Akdis, M., Burgler, S., Cramer, R., Eiwegger, T., Fujita, H., Gómez, E., Klunker, S., Meyer, S., O'Mahony, L., **Palomares, O.**, Rhyner, C., Quaked, N., Schaffartzik, A., Van de Veen, W., Zeller, S., Zimmermann, M., Akdis, C.A. ILs, from 1 to 37, and IFN- γ : Receptors, functions, and roles in diseases. **J Allergy Clin Immunol.** 2011;127:701-721. **IF: 11.320.**
 28. **Palomares, O.**, Yaman, G., Azkur, A.K., Akkoc, T., Akdis, M., Akdis, C.A. Role of T regulatory cells in immune regulation of allergic diseases. **Eur J Immunol.** 2010;40:1232-1240. **IF: 4.492**
- **EAACI Position Papers (20)**
1. Sokolowska M, Rovati GE, Diamant Z, Untersmayr E, Schwarze J, Lukasik Z, Sava F, Angelina A, **Palomares O**, Akdis C, O'Mahony L, Jesenak M, Pfaar O, Torres MJ, Sanak M, Dahlén SE, Woszczek G. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19. **Allergy.** 2022. doi: 10.1111/all.15258. **IF: 14.710**
 2. Jutel M, Torres MJ, **Palomares O**, Akdis CA, Eiwegger T, Untersmayr E, Barber D, Zemelka-Wiacek M, Kosowska A, Palmer E, Vieths S, Mahler V, Canonica WG, Nadeau K, Shamji MH, Agache I. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals- EAACI recommendations. **Allergy.** 2022. doi:10.1111/all.15252. **IF: 14.710**
 3. Bousquet J, Pfaar O, Agache I, Bedbrook A, Akdis CA, Canonica GW, Chivato T, Al-Ahmad M, Abdul Latiff AH, Ansotegui IJ, Bachert C, Baharuddin A, Bergmann KC, Bindslev-Jensen C, Bjermer L, Bonini M, Bosnic-Anticevich S, Bosse I, Brough HA, Brussino L, Calderon MA, Caraballo L, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Cepeda Sarabia AM, Chkhartishvili E, Chu DK, Cirule I, Cruz AA, Czarlewski W, Del Giacco S, Demoly P, Devillier P, Dokic D, Durham SL, Ebisawa M, El-Gamal Y, Emuzyte R, Gamkrelidze A, Fauquet JL, Fiocchi A, Fokkens WJ, Fonseca JA, Fontaine JF, Gawlik R, Gelincik A, Gemicioglu B, Gereda JE, Gerth van

Wijk R, Gomez RM, Gotua M, Grisle I, Guzmán MA, Haahtela T, Halken S, Heffler E, Hoffmann-Sommergruber K, Hossny E, Hrubisko M, Irani C, Ivancevich JC, Ispayeva Z, Julge K, Kaidashev I, Kalayci O, Khaitov M, Klimek L, Knol E, Kowalski ML, Kraxner H, Kull I, Kuna P, Kvedariene V, Kritikos V, Lauerma A, Lau S, Laune D, Levin M, Larenas-Linnemann DE, Lodrup Carlsen KC, Lombardi C, Lourenço OM, Mahboub B, Malling HJ, Manning P, Marshall GD, Melén E, Meltzer EO, Miculinic N, Milenkovic B, Moin M, Montefort S, Morais-Almeida M, Mortz CG, Mösges R, Mullol J, Namazova Baranova L, Neffen H, Nekam K, Niedozytko M, Odemyr M, O'Hehir RE, Ollert M, O'Mahony L, Ohta K, Okamoto Y, Okubo K, Pajno GB, **Palomares O**, Palkonen S, Panzner P, G Papadopoulos N, Park HS, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Plavec D, Popov TA, Recto M, Regateiro FS, Riggioni C, Roberts G, Rodriguez-Gonzales M, Rosario N, Rottem M, Rouadi PW, Ryan D, Samolinski B, Sanchez-Borges M, Serpa FS, Sastre J, Scadding GK, Shamji MH, Schmid-Grendelmeier P, Schünemann HJ, Sheikh A, Scichilone N, Sisul JC, Sofiev M, Solé D, Sooronbaev T, Soto-Martinez M, Soto-Quiros M, Sova M, Schwarze J, Skypala I, Suppli-Ulrik C, Taborda-Barata L, Todo-Bom A, Torres MJ, Valentin-Rostan M, Tomazic PV, Valero A, Toppila-Salmi S, Tsiligianni I, Untersmayr E, Urrutia-Pereira M, Valiulis A, Valovirta E, Vandenplas O, Ventura MT, Vichyanond P, Wagenmann M, Wallace D, Walusiak-Skorupa J, Wang Y, Wasserman S, Wong GW, Yorgancioglu A, Yusuf OM, Zernotti M, Zhang L, Zidarn M, Zuberbier T, Jutel M. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. **Clin Transl Allergy.** 2021; 9;11(4):e12014. doi: 10.1002/ct2.12014. IF: 5.871

4. Bousquet J, Agache I, Blain H, Jutel M, Ventura MT, Worm M, Del Giacco S, Benetos A, Bilo BM, Czarlewski W, Abdul Latiff AH, Al-Ahmad M, Angier E, Annesi-Maesano I, Atanaskovic-Markovic M, Bachert C, Barbaud A, Bedbrook A, Bennoor KS, Berghea EC, Bindslev-Jensen C, Bonini S, Bosnic-Anticevich S, Brockow K, Brussino L, Camargos P, Canonica GW, Cardona V, Carreiro-Martins P, Carriazo A, Casale T, Caubet JC, Cecchi L, Cherubini A, Christoff G, Chu DK, Cruz AA, Dokic D, El-Gamal Y, Ebisawa M, Eberlein B, Farrell J, Fernandez-Rivas M, Fokkens WJ, Fonseca JA, Gao Y, Gavazzi G, Gawlik R, Gelincik A, Gemicioglu B, Gotua M, Guérin O, Haahtela T, Hoffmann-Sommergruber K, Hoffmann HJ, Hofmann M, Hrubisko M, Illario M, Irani C, Ispayeva Z, Ivancevich JC, Julge K, Kaidashev I, Khaitov M, Knol E, Kraxner H, Kuna P, Kvedariene V, Lauerma A, Le LTT, Le Moing V, Levin M, Louis R, Lourenco O, Mahler V, Martin FC, Matucci A, Milenkovic B, Miot S, Montella E, Morais-Almeida M, Mortz CG, Mullol J, Namazova-Baranova L, Neffen H, Nekam K, Niedozytko M, Odemyr M, O'Hehir RE, Okamoto Y, Ollert M, **Palomares O**, Papadopoulos NG, Panzner P, Passalacqua G, Patella V, Petrovic M, Pfaar O, Pham-Thi N, Plavec D, Popov TA, Recto MT, Regateiro FS, Reynes J, Roller-Winsberger RE, Rolland Y, Romano A, Rondon C, Rottem M, Rouadi PW, Salles N, Samolinski B, Santos AF, S Sarquis F, Sastre J, M G A Schols J, Scichilone N, Sediva A, Shamji MH, Sheikh A, Skypala I, Smolinska S, Sokolowska M, Sousa-Pinto B, Sova M, Stelmach R, Sturm G, Suppli Ulrik C, Todo-Bom AM, Toppila-Salmi S, Tsiligianni I, Torres M, Untersmayr E, Urrutia Pereira M, Valiulis A, Vitte J, Vultaggio A, Wallace D, Walusiak-Skorupa J, Wang DY, Wasserman S, Yorgancioglu A, Yusuf OM, Zernotti M, Zidarn M, Chivato T, Akdis CA, Zuberbier T, Klimek L. Management of anaphylaxis due to COVID-19 vaccines in the elderly. **Allergy.** 2021; 76:2952-2964. doi: 10.1111/all.14838. IF: 14.710
5. Pfaar O, Agache I, Bonini M, Brough HA, Chivato T, Del Giacco SR, Gawlik R, Gelincik A, Hoffmann-Sommergruber K, Jutel M, Klimek L, Knol EF, Lauerma A, Ollert M, O'Mahony L, Mortz CG, **Palomares O**, Riggioni C, Schwarze J, Skypala I, Torres MJ, Untersmayr E, Walusiak-Skorupa J, Chaker A, Giovannini M, Heffler E, Jensen-Jarolim E, Quecchia C, Sandoval-Ruballos

- M, Sahiner U, Tomić Spirić V, Alvaro-Lozano M. COVID-19 pandemic and allergen immunotherapy-an EAACI survey. **Allergy**. 2021; 76(11):3504-3516. doi: 10.1111/all.14793. **IF: 14.710**
6. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D, Del Giacco S, Jutel M, Nadeau KC, **Palomares O**, Rabin RL, Riggioni C, Vieths S, Agache I, Shamji MH. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. **Allergy**. 2021, doi: 10.1111/all.14739. **IF: 14.710**
7. Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Boyman O, Caramori G, Cari L, Fan Chung K, Diamant Z, Eguiluz-Gracia I, Knol EF, Kolios A, Levi-Schaffer F, Nocentini G, **Palomares O**, Redegeld F, Van Esch B, Stellato C. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). **Allergy**. 2021;76(1):90-113. doi: 10.1111/all.14478. **IF: 14.710**
8. Sokolowska M, Rovati GE, Diamant Z, Untersmayr E, Schwarze J, Lukasik Z, Sava F, Angelina A, Palomares O, Akdis CA, O'Mahony L, Sanak M, Dahlen SE, Woszczek G. Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. **Allergy**. 2021;76(1):114-130. doi: 10.1111/all.14295. **IF: 14.710**
9. Pfaller B, José Yepes-Nuñez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, Bossios A, Boyman O, Chaker A, Chan S, Chatzipetrou A, du Toit G, Jutel M, Kauppi P, Kolios A, Li C, Matucci A, Marson A, Bendien S, Palomares O, Rogala B, Szepfalusi Z, Untersmayr E, Vultaggio A, Eiwegger T. Biologicals in atopic disease in pregnancy: An EAACI position paper. **Allergy**. 2021;76(1):71-89. doi: 10.1111/all.14282. **IF: 14.710**
10. Sokolowska M, Lukasik ZM, Agache I, Akdis CA, Akdis D, Akdis M, Barcik W, Brough HA, Eiwegger T, Eljaszewicz A, Eyerich S, Feleszko W, Gomez-Casado C, Hoffmann-Sommergruber K, Janda J, Jiménez-Saiz R, Jutel M, Knol EF, Kortekaas Krohn I, Kothari A, Makowska J, Moniuszko M, Morita H, O'Mahony L, Nadeau K, Ozdemir C, Pali-Schöll I, Palomares O, Papaleo F, Prunicki M, Schmidt-Weber CB, Sediva A, Schwarze J, Shamji MH, Tramper-Stranders GA, van de Veen W, Untersmayr E. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). **Allergy**. 2020;75(10):2445-2476. doi: 10.1111/all.14462. **IF: 13.146**
11. Vultaggio A, Agache I, Akdis CA, Akdis M, Bavbek S, Bossios A, Bousquet J, Boyman O, Chaker AM, Chan S, Chatzipetrou A, Feleszko W, Firinu D, Jutel M, Kauppi P, Klimek L, Kolios A, Kothari A, Kowalski ML, Matucci A, **Palomares O**, Pfaar O, Rogala B, Untersmayr E, Eiwegger T. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. **Allergy**. 2020;75(11):2764-2774. doi: 10.1111/all.14407. **IF: 13.146**
12. Klimek L, Hoffmann HJ, Kalpaklioglu AF, Demoly P, Agache I, Popov TA, Muraro A, Schmid-Grendelmeier P, Bonini S, Bonertz A, Mahler V, Vieths S, Pfaar O, Zuberbier T, Jutel M, Schmidt-Weber C, Hellings PW, Dreborg S, Bonini M, Brough HA, Bousquet J, Hoffmann-Sommergruber K, **Palomares O**, Ollert M, Shamji MH, Cardona V. In-vivo diagnostic test allergens in Europe: A call

- to action and proposal for recovery plan-An EAACI position paper. **Allergy**. 2020;75(9):2161-2169. doi: 10.1111/all.14329. IF: 13.146
13. Shamji MH, Akdis CA, Barber D, Canonica W, Chivato T, Del Giacco S, Hoffman-Sommergruber K, Jutel M, Knol E, Ollert M, O'Mahony L, Palomares O, Sastre J, Schwarze J, Smolinska S, Vieths S, Agache I. EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. **Allergy**. 2020;75(8):1899-1901. doi: 10.1111/all.14340. IF: 13.146
14. Jensen-Jarolim E, Bachmann MF, Bonini S, Jacobsen L, Jutel M, Klimek L, Mahler V, Mösges R, Moingeon P, O Hehir RE, **Palomares O**, Pfaar O, Renz H, Rhyner C, Roth-Walter F, Rudenko M, Savolainen J, Schmidt-Weber CB, Traidl-Hoffmann C, Kündig T. State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). **Allergy**. 2020;75(4):746-760. doi: 10.1111/all.14134. IF: 13.146
15. Pfaar O, Klimek L, Jutel M, Akdis CA, Bousquet J, Breiteneder H, Chinthrajah S, Diamant Z, Eiwegger T, Fokkens WJ, Fritsch HW, Nadeau KC, O'Hehir RE, O'Mahony L, Rief W, Sampath V, Schedlowski M, Torres M, Traidl-Hoffmann C, Wang DY, Zhang L, Bonini M, Brehler R, Brough HA, Chivato T, Del Giacco S, Dramburg S, Gawlik R, Gelincik A, Hoffmann-Sommergruber K, Hox V, Knol E, Lauerma A, Matricardi PM, Mortz CG, Ollert M, **Palomares O**, Riggioni C, Schwarze J, Skypala I, Untersmayr S, Walusiak-Skorupa J, Ansotegui I, Bachert C, Bedbrook A, Bosnic-Anticevich S, Brussino L, Canonica GW, Cardona V, Carreiro-Martins P, Cruz AA, Czarlewski W, Fonseca JA, Gotua M, Haatela T, Ivancevich JC, Kuna P, Kvedariene V, Larenas-Linnemann D, Latiff A, Morais-Almeida M, Mullol J, Naclerio R, Ohta K, Okamoto Y, Onorato GL, Papadopoulos NG, Patella V, Regateiro FS, Samolinski B, Suppli Ulrik C, Toppila-Salmi S, Valiulis A, Ventura MT, Yorgancioglu A, Zuberbier T, Agache I. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper. **Allergy**. 2020. doi: 10.1111/all.14453. IF: 13.146
16. Klimek L, Pfaar O, Worm M, Eiwegger T, Hagemann J, Ollert M, Untersmayr E, Hoffmann-Sommergruber K, Vultaggio A, Agache I, Bavbek S, Bossios A, Casper I, Chan S, Chatzipetrou A, Vogelberg C, Firinu D, Kauppi P, Kolios A, Kothari A, Matucci A, Palomares O, Szépfalusi Z, Pohl W, Hötzenecker W, Rosenkranz AR, Bergmann KC, Bieber T, Buhl R, Buters J, Darsow U, Keil T, Kleine-Tebbe J, Lau S, Maurer M, Merk H, Mösges R, Saloga J, Staubach P, Jappe U, Rabe KF, Rabe U, Vogelmeier C, Biedermann T, Jung K, Schlenker W, Ring J, Chaker A, Wehrmann W, Becker S, Freudelsperger L, Mülleneisen N, Nemat K, Czech W, Wrede H, Brehler R, Fuchs T, Tomazic PV, Aberer W, Fink-Wagner AH, Horak F, Wöhrl S, Niederberger-Leppin V, Pali-Schöll I, Pohl W, Roller-Wirnsberger R, Spranger O, Valenta R, Akdis M, Matricardi PM, Spertini F, Khaltaev N, Michel JP, Nicod L, Schmid-Grendelmeier P, Idzko M, Hamelmann E, Jakob T, Werfel T, Wagenmann M, Taube C, Jensen-Jarolim E, Korn S, Hentges F, Schwarze J, O Mahony L, Knol EF, Del Giacco S, Chivato Pérez T, Bousquet J, Bedbrook A, Zuberbier T, Akdis C, Jutel M. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärztverband Deutscher Allergologen (AeDA)^A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)^B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)^C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)^D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)^E, Österreichische

- Gesellschaft für Pneumologie (ÖGP)^F in co-operation with the German, Austrian, and Swiss ARIA groups^G, and the European Academy of Allergy and Clinical Immunology (EAACI)^H. **Allergol Select.** **2020**;4:53-68. doi: 10.5414/ALX02166E.
17. Klimek L, Pfaar O, Worm M, Eiwegger T, Hagemann J, Ollert M, Untersmayr E, Hoffmann-Sommergruber K, Vultaggio A, Agache I, Bavbek S, Bossios A, Casper I, Chan S, Chatzipetrou A, Vogelberg C, Firinu D, Kauppi P, Kolios A, Kothari A, Matucci A, **Palomares O**, Szépfalusi Z, Pohl W, Hötzenecker W, Rosenkranz A, Bergmann KC, Bieber T, Buhl R, Buters J, Darsow U, Keil T, Kleine-Tebbe J, Lau S, Maurer M, Merk H, Mösges R, Saloga J, Staubach P, Jappe U, Rabe C, Rabe U, Vogelmeier C, Biedermann T, Jung K, Schlenker W, Ring J, Chaker A, Wehrmann W, Becker S, Freudelsperger L, Mülleneisen N, Nemat K, Czech W, Wrede H, Brehler R, Fuchs T, Tomazic PV, Aberer W, Fink Wagner A, Horak F, Wöhrl S, Niederberger-Leppin V, Pali-Schöll I, Roller-Wirnsberger R, Spranger O, Valenta R, Akdis M, Matricardi PM, Spertini F, Khaltayev N, Michel JP, Nicod L, Schmid-Grendelmeier P, Idzko M, Hamelmann E, Jakob T, Werfel T, Wagenmann M, Taube C, Jensen-Jarolim E, Korn S, Hentges F, Schwarze J, O Mahony L, Knol E, Del Giacco S, Chivato T, Bousquet J, Zuberbier T, Akdis C, Jutel M. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie, a, b, c: Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA)^A, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)^B, der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)^C, der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI)^D, der Luxemburgischen Gesellschaft für Allergologie und Immunologie (LGAI)^E, der Österreichischen Gesellschaft für Pneumologie (ÖGP)^F in Kooperation mit der deutschen, österreichischen, und schweizerischen ARIA-Gruppe^G und der Europäischen Akademie für Allergologie und Klinische Immunologie (EAACI)^H. **Allergo J.** **2020**;29(4):14-27. German. doi: 10.1007/s15007-020-2553-y.
18. Agache I, Annesi-Maesano I, Bonertz A, Branca F, Cant A, Fras Z, Ingenrieth F, Namazova-Baranova L, Odemyr M, Spanevello A, Vieths S, Yorgancioglu A, Alvaro-Lozano M, Barber Hernandez D, Chivato T, Del Giacco S, Diamant Z, Eguiluz-Gracia I, van Wijk RG, Gevaert P, Graessel A, Hellings P, Hoffmann-Sommergruber K, Jutel M, Lau S, Lauerma A, Maria Olaguibel J, O'Mahony L, Ozdemir C, **Palomares O**, Pfaar O, Sastre J, Scadding G, Schmidt-Weber C, Schmid-Grendelmeier P, Shamji M, Skypala I, Spinola M, Spranger O, Torres M, Vereda A, Bonini S. Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases. **Allergy.** **2019**;74(11):2064-2076. doi: 10.1111/all.13856. **IF: 8.706**
19. Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Caramori G, Cari L, Chung KF, Diamant Z, Eguiluz-Gracia I, Knol EF, Kolios AGA, Levi-Schaffer F, Nocentini G, **Palomares O**, Puzzovio PG, Redegeld FA, van Esch BCAM, Stellato C. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. **Allergy.** **2019**;74(3):432-448. doi: 10.1111/all.13642. **IF: 8.706**
20. Boyman, O., Kaegi, C., Akdis, M., Bavbek, S., Bossios, A., Chatzipetrou, A., Eiwegger, T., Firinu, D., Harr, T., Knol, E., Matucci, A., **Palomares, O.**, Schmidt-Weber, C., Simon, H.U., Steiner, U.C., Vultaggio, A., Akdis, C.A., Spertini, F. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. **Allergy.** **2015**;70:727-754. **IF: 6.028**

- **Systematic reviews (8)**

1. Agache I, Song Y, Alonso-Coello P, Vogel Y, Rocha C, Solà I, Santero M, Akdis CA, Akdis M, Canonica GW, Chivato T, Del Giacco S, Eiwegger T, Fokkens W, Georgalas C, Gevaert P, Hopkins C, Klimek L, Lund V, Naclerio R, O'Mahony L, Palkonen S, Pfaar O, Schwarze J, Soyka MB, Wang Y, Zhang L, Canelo-Aybar C, **Palomares O***, Jutel M*. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. **Allergy**. **2021**; 76(8):2337-2353. doi: 10.1111/all.14809. IF: 13.146 ***Shared last authorship**
2. Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Solà I, Beltran J, Posso M, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong P, O'Mahony L, Schwarze J, Werfel T, Canelo-Aybar C, **Palomares O**, Jutel M. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. **Allergy**. **2021**; 76(1):59-70. doi: 10.1111/all.14547. IF: 13.146 ***Shared last authorship**
3. Agache I, Song Y, Posso M, Alonso-Coello P, Rocha C, Solà I, Beltran J, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Werfel T, Canelo-Aybar C, **Palomares O***, Jutel M.* Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. **Allergy**. **2021**;76(1):45-58. doi: 10.1111/all.14510. IF: 13.146 ***Shared last authorship**
4. Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Solà I, Beltran J, Posso M, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong P, O'Mahony L, Schwarze J, Werfel T, Canelo-Aybar C, **Palomares O***, Jutel M.* Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. **Allergy**. **2021**;76(1):59-70. doi: 10.1111/all.14547. IF: 13.146 ***Shared last authorship**
5. Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, Alonso-Coello P, Akdis C, Akdis M, Canonica W, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, **Palomares O***, Jutel M.* Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma. **Allergy**. **2020**;75:1043–1057. doi: 10.1111/all.14235. IF: 13.146 ***Shared last authorship**
6. Agache I, Song Y, Rocha C, Beltran J, Posso M, Steiner C, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C,

Palomares O*, Jutel M.* Efficacy and safety of treatment with dupilumab for severe asthma. *Allergy*. **2020**;75:1058–1068. doi: 10.1111/all.14268. **IF: 13.146** ***Shared last authorship**

7. Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, **Palomares O***, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. *Allergy*. **2020**;75:1023–1042. doi: 10.1111/all.14221. **IF: 13.146** ***Shared last authorship**
8. Dhami, S., Kakourou, A., Asamoah, F., Agache, I., Lau, S., Jutel, M., Muraro, A., Roberts, G., Akdis, C.A., Bonini, M., Cavkaytar, O., Flood, B., Gajdanowicz, P., Izuhara, K., Kalayci, Ö., Mosges, R., **Palomares, O.**, Pfaar, O., Smolinska, S., Sokolowska, M., Asaria, M., Netuveli, G., Zaman, H., Akhlaq, A., Sheikh, A. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. *Allergy*. **2017**;72:1825-1848. IF: 7.361

- **Guidelines (6)**

1. Agache I, Akdis C, Akdis M, Brockow K, Chivato T, Del Giacco S, Eiwegger T, Eyerich K, Giménez-Arnau A, Gutermuth J, Guttman-Yassky E, Maurer M, Ogg G, Ong PY, O'Mahony L, Schwarze J, Warner A, Werfel T, **Palomares O***, Jutel M*. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. *Allergy*. **2021**; doi: 10.1111/all.15030. **IF: 13.146** ***Shared last authorship**
2. Agache, I., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P.Y., O'Mahony, L., Schwarze, J., Warner, A., Werfel, T., **Palomares, O.*** and Jutel, M.* EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis. *Allergy*. **2021**. doi: 10.1111/all.146901. **IF: 13.146** ***Shared last authorship**
3. Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, Flood B, Firinu D, Gern JE, Hamelmann E, Hanania N, Hernández-Martín I, Knibb R, Mäkelä M, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Pfaar O, Quirce S, Sastre J, Shamji M, Schwarze J, **Palomares O***, Jutel M.* EAACI Biologicals Guidelines—Recommendations for severe asthma. *Allergy*. **2021**;76(1):14-44. doi: 10.1111/all.14425. **IF:13.146** ***Shared last authorship**
4. Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, Flood B, Gajdanowicz P, Izuhara K, Kalayci O, Mosges R, Palomares O, Papadopoulos NG, Sokolowska M, Angier E, Fernandez-Rivas M, Pajno G, Pfaar O, Roberts GC, Ryan D, Sturm GJ, van Ree R, Varga EM, van Wijk RG, Yepes-Nuñez JJ, Jutel M. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. *Allergy*. **2019**;74(5):855-873. doi: 10.1111/all.13749. **IF: 8.328**

5. Bonertz, A., Roberts, G., Slater, J.E., Bridgewater, J., Rabin, R.L., Hoefnagel, M., Timon, M., Pini, C., Pfaar, O., Sheikh, A., Ryan, D., Akdis, C., Goldstein, J., Poulsen, L.K., van Ree, R., Rhyner, C., Barber, D., **Palomares, O.**, Pawankar, R., Hamerlijnk, D., Klimek, L., Agache, I., Angier, E., Casale, T., Fernandez-Rivas, M., Halken, S., Jutel, M., Lau, S., Pajno, G., Sturm, G., Varga, E.M., Gerth van Wijk, R., Bonini, S., Muraro, A., Vieths, S. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. **Allergy** **2018**;73:816-826. IF: 7.361
 6. Bonertz, A., Roberts, G.C., Hoefnagel, M., Timon, M., Slater, J.E., Rabin, R.L., Bridgewater, J., Pini, C., Pfaar, O., Akdis, C., Goldstein, J., Poulsen, L.K., van Ree, R., Rhyner, C., Barber, D., **Palomares, O.**, Sheikh, A., Pawankar, R., Hamerlijnk, D., Klimek, L., Agache, I., Angier, E., Casale, T., Fernandez-Rivas, M., Halken, S., Jutel, M., Lau, S., Pajno, G., Sturm, G., Varga, E.M., Gerth van Wijk, R., Bonini, S., Muraro, A., Vieths, S. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. *Allergy*. 2017;73:64-76. IF: 7.361
- **Book Chapters (6)**
1. López-Abente, J and **Palomares, O.** 2nd Edition of the Global Atlas of Asthma. Chapter 94: The adaptive immune response in asthma – T cells. April 2021. Published by European Academy of Allergy and Asthma Immunology (EAACI). Editors Ioana Agache and Cezmi Akdis. Section B Mechanisms, phenotypes and endotypes. p 95., Switzerland.
 2. Figueras Nart, I. **Palomares, O.** Dermatitis. Chapter: Atopic dermatitis: from physiopathology to the clinics. 2020, ISBN: 978-1-78985-554-8 Edited by: Dr. Eleni Papakonstantinou. IntechOpen Limit ed. United Kingdom
 3. **Palomares, O.**, Cezmi Akdis, C.A. Chapter 20: Immunology of the asthmatic response. 2020, ISBN: 978-03-2367-462-1. Edited by: Dr. Donald Leung. Elsevier ed. USA.
 4. **Palomares, O.**, Angelina, A., Benito-Villalvilla, C. Martín-Cruz, L. Diagnóstico, monitorización y tratamiento inmunológico de las enfermedades alérgicas. Capítulo 4: "Inmunoterapia no específica de alérgeno". 2018, ISBN: 978-84-9113-240-0. Edited by: Miguel González Muñoz y José Luis Subiza. Elsevier ed. Spain
 5. **Palomares, O.**, Akdis, C.A. Pediatric Allergy. Principles and Practice. Chapter 28: Immunology of the asthmatic response. 2015, ISBN: 978-0-323-29875-9. Edited by: Leung & Szeffler & Bonilla & Akdis & Sampson. 3rd edition. Elsevier ed. USA
 6. **Palomares, O.**, Rhyner, C. Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis. Chapter 12: Biotechnology for the diagnosis of Allergic Rhinitis. 2015, Published by European Academy of Allergy and Asthma Immunology (EAACI), Section D Allergic Rhinitis Diagnosis, pp 182-184. Switzerland

2. PROJECTS

7 selected projects as Principal Investigator from a total of 17 projects

Reference of the Project: PID2020-114396RB-I00.

Title: "Cannabinoides y mecanismos moleculares implicados en la regulación de células dendríticas y epiteliales humanas: Nuevas estrategias basadas en cannabinoides para la alergia".

Financial Entity: Ministerio de Ciencia e Innovación (MICIIN).

Length: from 01/09/2021 to 31/08/2024.

Contribution: Principal Investigator

Reference: RTC2019-007097-1.

Title: "Nuevas vacunas contra alergias alimentarias".

Financial Entity: Ministerio de Ciencia, Innovación y Universidades. "Retos Colaboración".

Length: from 01/01/2019 to 31/12/2023.

Contribution: Principal Investigator

Reference: IND2019/BMD-17182.

Title: "Estudio de los mecanismos moleculares asociados a la inmunomodulación de vacunas bacterianas en asma alérgica."

Financial Entity: Comunidad de Madrid (CAM). Ayudas para la realización de doctorados industriales.

Length: from 01/01/2020 to 31/12/2022.

Contribution: Principal Investigator

Reference of the project: SAF2017-84978-R

Title: "Cannabinoids and metabolic reprogramming in human dendritic cells: Novel therapies for the prevention and treatment of severe asthma"

Financial Entity: Ministerio de Economía y Competitividad (MINECO)

Length: from: 01/01/2018 to: 31/12/2020

Contribution: Principal Investigator

Reference of the project: SAF2014-52706-R

Title: "Cannabinoids and immunoregulation of the allergic diseases: Design of novel vaccines targeting DCs for allergen-specific immunotherapy"

Financial Entity: Ministerio de Economía y Competitividad (MINECO)

Length: from: 01/01/2015 to: 31/12/2017

Contribution: Principal Investigator

Reference of the project: FEI 16/60_4159073

Title: "Functional Studies in human DCs to generate novel vaccines"

Financial Entity: Universidad Complutense de Madrid (UCM)

Length: from 01/09/2016 to: 31/08/2019

Contribution: Principal Investigator

Reference of the project: IPT-2012-0639-090000

Title: "Development of immunostimulatory therapies based on bacterial products to prevent recurrent respiratory tract infections in children and adults"

Financial Entity: Ministerio de Economía y Competitividad (MINECO)

Length: from: 01/01/2013 to: 31/12/2014

Contribution: Principal Investigator

Contracts with Pharmaceutical Companies:**7 selected projects as Principal Investigator from a total of 14 projects**

Ref: Art. 83. 100449954/2023. "Study of the capacity of TSLP to promote metabolic and epigenetic reprogramming in human dendritic cell subsets and their functional consequences in the development and maintenance of pathological immune responses"

Company: Astra Zeneca/Amgen.

Start and end dates: 01/01/2023 to 31/12/2024.

Principal Investigator: Oscar Palomares.

Ref: Art. 83. 4157786_140/2020. "Study of the potential stronger capacity of ligelizumab to induce functional regulatory T (Treg) cells in comparison to omalizumab".

Company: Novartis Pharma AG.

Start and end dates: 27/05/2020 to 30/12/2022.

Principal Investigator: Oscar Palomares.

Ref: Art. 83. 4156705_414/2017. "Study of the capacity of Omalizumab to promote the induction of functional regulatory T (Treg) cells in comparison to corticosteroids".

Company: Novartis Pharma AG.

Start and end dates: 01/04/2018 to 31/12/2020.

Principal Investigator: Oscar Palomares.

Ref: Art. 83. 4156611_272/2017. "Inmunomoduladores bacterianos y fúngicos: efectos en células del sistema inmunológico de pacientes con vulvovaginitis candidiásica recurrente".

Company: Inmunotek S.L.

Start and end dates: 30/09/2019 to 06/02/2021.

Principal Investigator: Oscar Palomares.

Ref: Art. 83. 4155462_223/2014. "Estudio de los mecanismos inmunológicos inducidos por nuevas vacunas para el tratamiento de la alergia en células dendríticas humanas".

Company: Inmunotek S.L.

Start and end dates: 01/01/2015 to 20/05/2017.

Principal Investigator: Oscar Palomares.

Ref: Art.83. 4153049_132/2013. "Determination of medium and long chain free fatty acids in plasma from healthy subjects and asthmatic patients".

Company: SIAF, Davos, Switzerland.

Start and end dates: 01/04/2014 to 31/12/2016.

Principal Investigator: Oscar Palomares.

Ref: Art. 83 4154605_138/2013, 24/2013. "Estudios fenotípicos y funcionales inducidos por nuevas vacunas en células dendríticas humanas".

Company: Inmunotek S.L.

Start and end dates: 01/09/2012 hasta 31/12/2014.

Principal Investigator: Oscar Palomares.

3. PATENTS

Inventors: **Palomares O**, Jaumont X, Tassinari, P, Pfister P.

Title: methods of preventing or treating diseases or disorders involving dysfunctioning of regulatory T cells, using an anti-IgE antibody, e.g., omalizumab.

Reference Number: PAT05894-EP-EPA (Europe).

Entity: Patent transferred to Novartis Pharma AG.

Inventors: **Palomares O**, Jaumont X, Tassinari, P, Pfister P.

Title: methods of preventing or treating diseases or disorders involving dysfunctioning of regulatory T cells, using an anti-IgE antibody, e.g., omalizumab.

Reference Number: PAT05894-WO-PCT (Rest of the world).

Entity: Patent transferred to Novartis Pharma AG.

Inventors: Rodríguez, R., Villalba, M., Batanero, E., **Palomares, O.**, Sirvent, S.

Title: DNA que codifica el alérgeno de mostaza amarilla (*Sinapis alba*) Sin a 3, y sus aplicaciones.

Reference Number: P200900744 Spain.

Entity: Universidad Complutense de Madrid (UCM).

4. OTHER CONTRIBUTIONS

4.1. Evaluation of research projects and grants

- Asthma UK Project Grants, 2013, UK.
- Programme Blanc Edition 2013 (*Agence Nationale de la Recherche*), France.
- Projects and grants from SEAIC 2014, España.
- Mitacs Accelerate Proposals 2014, Canada.
- Sanofi Genezyme Innovation Grants; Type 2, 2018, 2020 and 2021 Sanofi.
- Agencia Estatal de Investigación (AEI), Ministerio de Ciencia e Innovación, 2018-continue and "Comisionado del panel BME-IIT" 2019- .
- Instituto de Salud Carlos III, Evaluaciones FIS, 2018-continue and "Comisionado del panel-Proyectos de investigación en salud (AES 2020)" 2020- .
- Becas predoctorales para AEI, MINECO, 2018.

4.2. Editorial Boards

- Associate Editor *Frontiers in Allergy*, 2020-continue
- Associate Editor *Int Arch Allergy Immunol* (IF: 2.985), 2018-continue
- Editorial Board *Allergy* (IF: 13.146), 2015-continue
- Editorial Board *Clin Exp Allergy* (IF: 5.018), 2021-continue
- Editorial Board *J Allergy Clin Immunol* (IF: 10.228), 2022-continue
- Editor-in-Chief *EAACI knowledge Hub*, 2022-continue

4.3. Congress and international conferences

- More than 100 invited conferences** at national and international congresses
- Participation in the **organization of 25 international congresses**
- Chair of more than 50 scientific sessions**

4.4. Societies

- Sociedad Española de Inmunología (SEI). 2014-Continue.
- American Academy of Allergy Asthma & Immunology (AAAAI). 2014-Continue.
- European Academy of Allergy and Clinical Immunology (EAACI). 2001-continue
- Sociedad Española de Bioquímica y Biología Molecular (SEBBM). 2002-Continue.

4.5. Awards

- **EFIS-IL Lecture Award 2022** by the Austrian Society of Allergology and Immunology (ÖGAI)
- **EAACI PhARF Award 2021** XL EAACI hybrid congress. Madrid/Krakow, Spain/Poland
- **The 12th Allergopharma award 2012** XXXI EAACI Congress. Geneva, Switzerland
- **International Young Investigator Award 2014** AAAAI meeting, San Diego, USA
- **Premio extraordinario de Doctorado** (UCM, 2005).